Alcohol septal ablation in hypertrophic obstructive cardiomyopathy: do sex, mitral valve leaflet length and septal thickness affect the outcome?

Introduction

Hypertrophic obstructive cardiomyopathy (HOCM) is the most severe form of hypertrophic cardiomyopathy (HCM) where basal septal hypertrophy contributes to left ventricular outflow tract obstruction (LVOTO) and the patients also have increased risk of arrhythmias [1]. In addition to the hypertrophy of the septum, systolic anterior motion and abnormalities of the mitral valve leaflets are other known pathophysiological mechanisms behind LVOTO in patients with HOCM [2, 3]. Pharmacological treatment in HOCM aims to reduce the symptoms associated with LVOTO [1]. In instances where pharmacological treatment cannot mitigate severe symptoms and disease progress, alcohol septal ablation (ASA) is one of the recommended interventions for treatment of HOCM and LVOTO. ASA is a percutaneous procedure where a regional percutaneous alcohol injection is performed to induce a focal myocardial infarction in a selected part of the basal left ventricular septal wall, rendering a reduced septal wall thickness and LVOTO [4]. Compared to alternative surgical procedures such as myectomy, ASA is associated with shorter recovery time, faster intervention time, and fewer risks associated with cardiac surgery [5]. However, the proportion of patients that do not respond to ASA leading to further re-interventions is higher among patients undergoing ASA (5-25%) compared with surgical myectomy (<1%) [6, 7]. The reason for the higher re-intervention rate is not entirely understood.

Additional to the hypertrophic septum, patients with HCM may have elongated mitral valve leaflets in comparison to healthy controls, inducing further risk of developing LVOTO [3]. However, the impact of sex, pre-procedural basal septal wall thickness (BSWT) and mitral valve leaflet length (MVLL) on success rate in patients with HOCM undergoing ASA has been less studied. Therefore, this study aims to investigate if sex, BSWT and MVLL, are associated with remaining LVOTO in patients with HOCM, undergoing ASA.

Methods

Data collection

Patient data

Patient data as well as ASA specific data were collected from patient records, and from imaging systems: left-heart catheterization (CATH) (PACS), and ECHO data (Viewpoint). The data for each patient were collected from the three different time points; from the pre-procedural ECHO performed at maximum one week prior to ASA; CATH and ECHO during the ASA, and a follow up ECHO one year after ablation. Any values missing from the patients’ files were registered as missing values.

ECHO

All ECHO examinations were performed by personnel highly experienced in cardiac imaging using advanced ultrasound machines for cardiac imaging. The image acquisition was performed according to standard protocol including additional images focusing on HCM specific morphological and Doppler findings (as described below) to enable comprehensive HCM evaluation [8].

Pre-procedural ECHO

The data collected from the pre-ECHO was: age, sex, heart rate (beats per minute, BPM), weight, length, body surface area (BSA), LV end-diastolic and end-systolic diameters, LV end-diastolic and end-systolic volume, left atrium (LA) end-systolic volume, LV BSWT (Fig. 1) and posterior wall thickness [9]. Further, the grade of mitral- and aortic regurgitation, presence of SAM and LVOT peak systolic velocity and gradients at rest and Valsalva, estimated from LVOT velocity using the simplified Bernoulli equation (ΔP=4V²) were collected. For MV specific assessment, the length of the MV leaflets was measured [8] from the preoperative ECHO images (Fig. 1). The morphological measurements of the anterior mitral leaflet (AML) and posterior mitral leaflet (PML) length were made in the apical three-chamber view (A3C) at end-diastole (n=142, 92%). Among patients with poor visualization in A3C, the measurements were done in parasternal long axis view (PLAX) (n=9, 6%). Two ECHO examinations had too poor visualization to allow the MV specific measurements, these MV specific data were registered as missing (n=2, 1%). Data from one patient where the ECHO images were inaccessible were registered as missing (n=1, 1%).

• Download figure
• Open in new tab

Fig. 1 Measures of mitral valve leaflet length and basal septal wall thickness in pre-procedural ECHO images.

A. Mitral valve leaflet length, red line: posterior mitral leaflet length, yellow line: anterior mitral leaflet length. B. Basal septal wall thickness, blue line: basal septal wall thickness.

Periprocedural invasive pressure measurements

Invasive intracardiac pressure measurements were performed using the standard end-hole fluid-filled catheters and recorded and stored using Exper Cardio System (Philips Healthcare). Data from pressure measurement were collected continuously throughout the ASA. The pressure gradients were measured invasively and simultaneously during CATH with one catheter placed in the LV and one in the ascending aorta. The following data was collected: heart rhythm, heart rate, LV peak systolic, early- and late diastolic pressures, peak systolic and diastolic pressures in the ascending aorta, both at rest and at Valsalva maneuver (Valsalva) and/or during induced premature ventricular contractions (PVC). Peak-to-peak systolic pressure gradient across LVOT was calculated as the difference between LV peak systolic pressure and aortic peak systolic pressure. Resting and provoked LVOT peak-to-peak gradients were calculated prior to, and 10 minutes after alcohol administration at the end of the ASA procedure. The amount of injected alcohol was registered.

Follow-up

The following data was collected from the one-year follow-up: average days until follow-up, pacemaker or ICD implantation, number of re-interventions (ASA or myectomy). ECHO data collected from the one-year follow-up: prevalence of SAM, BSWT, LV end-diastolic diameter (LVEDd), maximal LVOT velocity and gradients at rest and Valsalva, estimated from maximal LVOT velocity using the simplified Bernoulli equation (ΔP=4V ²). Remaining LVOTO was defined as a peak instantaneous gradient across LV outflow of at least 30 mmHg, either at rest or on provocation derived from the ECHO examination at the one-year follow-up, or from the most recent ECHO examination before re-intervention for the patients that underwent re-intervention.

Statistical analysis

To verify if continuous data were normally distributed, Shapiro-Wilk test was used. Normally distributed data were presented with mean ± standard deviation (SD). Non-normally distributed data were presented with median and interquartile range (IQR). Binary variables were reported as absolute numbers and percentages. To evaluate the correlation between sex, the AML length, the PML length, the BSWT, and the amount of alcohol injected, and outcome (remaining LVOTO) after ASA, logistic and linear regression models were executed. The linear regression models were adjusted for sex and age. To assess a cutoff value if any BSWT was associated with better outcome at follow-up, a number of cutoffs ranging from the different values in the IQR of BSWT were tried using logistic regression. P-values <0.05 were considered significant. Inter- and intra-observer variability of measures of BSWT, length of AML and PML, was calculated using intra-class correlation (ICC). Data analysis was conducted using STATA software (version 17.0 Stata Corp., College Station, Texas, USA).

Results

Intra-procedural invasive measurements and acute hemodynamic effects of ASA

The systolic pressures and peak-to-peak systolic pressure gradients pre- and post-ASA at rest and at Valsalva/PVC are presented in Figure 2. There was no significant change in the systolic aortic pressure pre- and post-ASA, however there was a significant decrease in the LV peak systolic pressure and LVOT peak-to-peak pressure gradient post-ASA compared to pre-ASA, at both rest and Valsalva.

• Download figure
• Open in new tab

Fig. 2 Comparison between invasive systolic left ventricular pressure gradients before (dark grey) and after (light grey) alcohol septal ablation at rest and during Valsalva/PVC.

Values are expressed as median and interquartile ranges. *Statistically significant p values. Abbreviations: LV – Left ventricle, LVOT – Left ventricular outflow tract, PSP – peak systolic pressure, PVC – Induced premature ventricular contraction.

Discussion

This single-center retrospective cohort study aimed to assess if there were any associations between sex, BSWT, AML length, PML length, and outcomes after ASA-treatment for HOCM. In general, patients with BSWT >23 mm had a significantly higher rate of remaining LVOTO at follow-up. Most patients had elongated MVLL, however AML and PML length were not associated with remaining LVOTO at follow-up. Further, the amount alcohol injected during ASA was not associated with remaining LVOTO at follow-up. These results suggest that BSWT could be a possible predictive value for LVOTO reduction after ASA, however there is a need for further studies of potential anatomical predictors of HOCM-patients, to enable optimized treatment based on individual conditions.

At the one-year follow-up, 14% of the patients had remaining LVOTO, which is adherent to a recent review of ASA showing 10-20% of patients have a residual gradient > 30 mmHg after ASA [10]. Supportive to this study, showing that BSWT >23 mm had a significantly higher rate of remaining LVOTO at follow-up, it has previously been shown that BSWT is associated with LVOTO in patients with HOCM [11]. Further supportive, a study of 531 HOCM-patients with follow-up time 0.6±0.6 years after ASA, showed that patients with thicker septum had a higher residual LVOTO on follow-up compared to patients with a thinner septum [12]. That study had 3 cutoffs: <20mm, 20-24mm, ≥25mm, where the ≥25mm group showed a trend of higher residual gradients on follow-up although of no significance compared to the other groups [12]. Additionally, a study by Lu et al. with 102 HOCM patients found that a septum thinner than 24.3 mm had a higher rate of LVOT gradient reduction defined as a 50% reduction compared to the gradient before ASA, and patients with a septal thickness of >24.3 mm had more non-responders [13]. The authors suggested having 24.3 mm as a cutoff when considering treating patients with ASA since a significant number of patients with a septum thicker than that were non-responders and had worse outcome in form of LVOT gradient reduction [13]. Their study had a different definition of LVOT reduction, with a 50% reduction in LVOT gradient between pre procedural examination and follow-up. In summary, BSWT seems to be a promising predictive value for LVOTO reduction after ASA.

In this study, the amount of alcohol injected during the procedure was not associated with remaining LVOTO at follow-up. The mean amount of alcohol injected during the ASA in this study (1.6 ± 0.3 mL) is lower than in previous studies reporting mean alcohol doses of 2.1-2.2 mL [14]. However, the BSWT this study was lower (mean 19 mm) than in the study for comparison (20.1-20.7 mm). Although the recommended dose of alcohol in ASA is 1 mL per 10 millimeters of BSWT [15], the amount of alcohol per 10 millimeters of BSWT is this study equaled 0.85 ± 0.2 mL/mm, which is lower than the recommended dose. This could possibly explain some of the cases of remaining LVOTO after ASA. At the one-year follow-up, one patient had undergone surgical myectomy and 13 (9%) patients had undergone re-ablation. Hence, 7 patients with remaining LVOTO after ASA did not undergo re-intervention during the first year after ASA, although some of these patients could have undergone re-intervention later than one year after ASA or they might have had a relief of symptoms as the LVOT gradient could have been reduced although > 30 mmHg.

Elongation of the AML and PML (as compared to normal reference range [11]) was observed in most patients in this study, in-line with previous studies of patients HOCM suggesting elongated MV leaflets as being part of the innate HCM phenotype [11,16–18]. Although the correlation between MVLL and outcome after ASA has not yet been shown. Lentz Carvalho et al. examined the effect of AML length in relation to outcomes after septal myectomy in 564 patients with HOCM and suggested that AML length ≥ 30 mm had no correlation with remaining LVOTO [3]; however, the study did not extent to assessment of possible sex differences. The finding that BSA-indexed valve leaflet lengths were significantly longer in women in this study, highlight a possible persistent functional difference that need to be further studied. Further, this study presents that women had a higher prevalence of post-operative complications (i.e. atrioventricular block) than men. This is supported by a study by Saravanabavanandan et al. shown that women have higher short-term all-cause mortality, incidence of atrioventricular block, permanent pacemaker implantation and hospital stay after ASA or myectomy, compared to men [19]. In both, this study and the study by Saravanabavanandan et al., women were older at the time of the procedure.

Conclusion

This study suggests that pre-procedural septal thickness >23 mm was associated with remaining LVOTO at follow-up one year after ASA. Length of AML and PML, and sex do not seem to contribute significantly to remaining LVOTO. Most patients with HOCM had elongated MVLL, which supports the notion of elongated MV leaflets in patients with HOCM. In summary, these findings suggest that BSWT measured with ECHO can be used effectively for patient selection for successful ASA. A severe basal septal hypertrophy in HOCM may be associated with a poor outcome after ASA. There is a need for further studies of potential sex differences and detectable differences in the anatomy of HOCM-patients, to enable optimized treatment based on individual conditions.

Statements & Declarations